Efficacy and Safety of Two Treatment Regimens of Topical MOB015 in Adults With Distal Subungual Onychomycosis
Primary Purpose
Onychomycosis
Status
Completed
Phase
Phase 2
Locations
Sweden
Study Type
Interventional
Intervention
MOB015
Sponsored by
About this trial
This is an interventional treatment trial for Onychomycosis focused on measuring distal subungual onychomycosis
Eligibility Criteria
Inclusion Criteria:
- Male or female
- 18 - 70 years
- DSO of at least one of the great toe(s) affecting 25 % to 75 % of the target nail (verified by blinded assessor before randomization)
- Positive culture for dermatophytes (i.e. Trichophyton species; T. rubrum or T. mentagrophytes)
- Signed written informed consent
Exclusion Criteria:
- Proximal subungual onychomycosis
- DSO of both great toenails where involvement has extended into the proximal portion of the target nail (unaffected proximal nail is less than 2 mm)
- "Spike" of onychomycosis extending to eponychium of the target nail
- Presence of dermatophytoma (defined as demarcated and localised thick masses of fungal hyphae and necrotic keratin between the nail plate and nail bed) on the target nail
- Other conditions than DSO known to cause abnormal nail appearance
- Topical antifungal treatment of the nails within 1 month before screening
- Systemic use of antifungal treatment within 3 months before screening
- Signs of severe peripheral circulatory insufficiency
- Immunosuppression
- Participation in another clinical trial with an investigational drug or device during the previous 4 weeks before screening
- Known allergy to any of the tested treatment products
- A pregnancy test indicating pregnancy in a woman of childbearing potential at screening (visit 1)
Pre-menopausal (last menstruation ≤ 1 year prior to screening) sexually active women who :
- are pregnant or nursing
- are not surgically sterile
- are of child bearing potential and not practising an acceptable method of birth control, or does not plan to continue practising an acceptable method of birth control throughout the trial (acceptable methods include intrauterine
Sites / Locations
- 15 Locations
Arms of the Study
Arm 1
Arm 2
Arm Type
Active Comparator
Active Comparator
Arm Label
MOB015 for 3 months
MOB015 for 9 months
Arm Description
Outcomes
Primary Outcome Measures
Mycological cure of target nail at 12 months, defined as negative fungal culture and negative direct microscopy.
Secondary Outcome Measures
Proportion of patients with negative fungal culture, negative direct microscopy and complete cure.
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT01246518
Brief Title
Efficacy and Safety of Two Treatment Regimens of Topical MOB015 in Adults With Distal Subungual Onychomycosis
Official Title
An Open, Multi-centre Trial Comparing the Efficacy and Safety of Two Different Treatment Regimens of Topical MOB015 Treatment of Distal Subungual Onychomycosis (DSO)
Study Type
Interventional
2. Study Status
Record Verification Date
September 2011
Overall Recruitment Status
Completed
Study Start Date
December 2010 (undefined)
Primary Completion Date
October 2012 (Actual)
Study Completion Date
October 2012 (Actual)
3. Sponsor/Collaborators
Name of the Sponsor
Moberg Pharma AB
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
Onychomycosis is a fungal infection that affects fingernails and/or toenails.
The purpose of this trial is to investigate if MOB015 is effective and safe for treatment of patients with fungal infection of the toenails.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Onychomycosis
Keywords
distal subungual onychomycosis
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
250 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
MOB015 for 3 months
Arm Type
Active Comparator
Arm Title
MOB015 for 9 months
Arm Type
Active Comparator
Intervention Type
Drug
Intervention Name(s)
MOB015
Intervention Description
Arm 1; MOB015 once a day for 3 months. Arm 2; MOB015 once a day for 9 months.
Primary Outcome Measure Information:
Title
Mycological cure of target nail at 12 months, defined as negative fungal culture and negative direct microscopy.
Time Frame
12 months
Secondary Outcome Measure Information:
Title
Proportion of patients with negative fungal culture, negative direct microscopy and complete cure.
Time Frame
1, 3, 6, 9, 12 months.
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
70 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Male or female
18 - 70 years
DSO of at least one of the great toe(s) affecting 25 % to 75 % of the target nail (verified by blinded assessor before randomization)
Positive culture for dermatophytes (i.e. Trichophyton species; T. rubrum or T. mentagrophytes)
Signed written informed consent
Exclusion Criteria:
Proximal subungual onychomycosis
DSO of both great toenails where involvement has extended into the proximal portion of the target nail (unaffected proximal nail is less than 2 mm)
"Spike" of onychomycosis extending to eponychium of the target nail
Presence of dermatophytoma (defined as demarcated and localised thick masses of fungal hyphae and necrotic keratin between the nail plate and nail bed) on the target nail
Other conditions than DSO known to cause abnormal nail appearance
Topical antifungal treatment of the nails within 1 month before screening
Systemic use of antifungal treatment within 3 months before screening
Signs of severe peripheral circulatory insufficiency
Immunosuppression
Participation in another clinical trial with an investigational drug or device during the previous 4 weeks before screening
Known allergy to any of the tested treatment products
A pregnancy test indicating pregnancy in a woman of childbearing potential at screening (visit 1)
Pre-menopausal (last menstruation ≤ 1 year prior to screening) sexually active women who :
are pregnant or nursing
are not surgically sterile
are of child bearing potential and not practising an acceptable method of birth control, or does not plan to continue practising an acceptable method of birth control throughout the trial (acceptable methods include intrauterine
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Jan Faergemann, MD, PhD
Organizational Affiliation
Dept. of Dermatology, Sahlgrenska University Hospital, Gothenburg, Sweden
Official's Role
Principal Investigator
Facility Information:
Facility Name
15 Locations
City
Sweden
Country
Sweden
12. IPD Sharing Statement
Learn more about this trial
Efficacy and Safety of Two Treatment Regimens of Topical MOB015 in Adults With Distal Subungual Onychomycosis
We'll reach out to this number within 24 hrs